Avidity Biosciences
We are delivering a new class of RNA therapeutics - AOCs - which combine the specificity of monoclonal antibodies and the precision of oligonucleotides. Through integrating these proven technologies, our AOC platform is able to deliver to previously inaccessible tissue and cell types and more effectively target the underlying genetic drivers of diseases. With an agile and diverse team, we are advancing and expanding our pipeline programs to offer treatment options for patients and their families
Basic Information
- Category: RNA Therapeutics
- Founded: 2012
- Headquarters: San Diego, CA
- Website: aviditybiosciences.com
Documented Facts
- Phone: 8584017900 (No linked source recorded for this statement.)
- Email: info@aviditybio.com (No linked source recorded for this statement.)
Evidence and Sources
- Avidity Biosciences — Official Site (official)
- Avidity Biosciences on linkedin (social)
Citation Guidance
Explore RNA Therapeutics profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Avidity Biosciences.
- Canonical profile: https://brandsource.ai/brands/avidity-biosciences
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/avidity-biosciences/json-ld
- Citation profile API: https://brandsource.ai/api/brands/avidity-biosciences/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (84/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T04:26:06.536Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We are delivering a new class of RNA therapeutics - AOCs - which combine the specificity of monoclonal antibodies and the precision of oligonucleotides. Through integrating these proven technologies, our AOC platform is able to deliver to previously inaccessible tissue and cell types and more effectively target the underlying genetic drivers of diseases. With an agile and diverse team, we are advancing and expanding our pipeline programs to offer treatment options for patients and their families
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.